بدائل البحث:
teer decrease » greater decrease (توسيع البحث)
gap decrease » gain decreased (توسيع البحث), step decrease (توسيع البحث), _ decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
teer decrease » greater decrease (توسيع البحث)
gap decrease » gain decreased (توسيع البحث), step decrease (توسيع البحث), _ decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
-
7281
Process execution halted due to deadlock.
منشور في 2024"…Additionally, the DBDAA introduces a primary unsafe sequence mechanism that enhances the acceptability and efficiency of the algorithm by allowing processes to participate in safety checks repeatedly after a predetermined amount of system-defined time. …"
-
7282
Baseline Characteristics of Study Participants.
منشور في 2025"…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …"
-
7283
Raw and processed data files.
منشور في 2025"…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …"
-
7284
The flow chart of the study.
منشور في 2025"…Hematocrit in the first 2 hours of life, considered as a continuous variable, was significantly associated with short-term outcomes in univariate analyses (P < 0.05). …"
-
7285
Baseline characteristics of participants.
منشور في 2025"…Hematocrit in the first 2 hours of life, considered as a continuous variable, was significantly associated with short-term outcomes in univariate analyses (P < 0.05). …"
-
7286
Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i>
منشور في 2024"…In this regard, bioderived nanovesicles have shown significant promise. This work demonstrated significant antibacterial properties of extracellular nanovesicles derived from plant (mint) leaf juice (MENV). …"
-
7287
Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i>
منشور في 2024"…In this regard, bioderived nanovesicles have shown significant promise. This work demonstrated significant antibacterial properties of extracellular nanovesicles derived from plant (mint) leaf juice (MENV). …"
-
7288
-
7289
pHI for net status.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7290
Combined net integrity PBO and LLINs-PLOS1.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7291
Factors affecting pyrethroid-LLINs integrity.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7292
Factors associated with mosquito net integrity.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7293
LLINs knockdown performance over time.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7294
Factors affecting PBO-LLINs integrity.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7295
Net bioefficacy data.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7296
House structure and status.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7297
LLINs hole positions over time.
منشور في 2025"…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…"
-
7298
-
7299
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7300
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"